(No. 170) numares AG, a system provider of innovative in-vitro diagnostic systems based at BioPark Regensburg has successfully completed another financing round. The investors include Wachstumsfonds Bayern, a Bavarian growth fund managed by Bayern Kapital that will provide €2 million. The additional funds will be used to expand the development pipeline and fuel the company's continued international expansion.
(No. 169) The University Clinic in Regensburg and the Caritas Hospital St. Josef in Regensburg have brought the "Comprehensive Cancer Center Ostbayern" (CCCO) to life. The CCCO contributes to establising the highest medical standards for oncology and developing new diagnostic and treatment processes.
(No. 169) The Biotech company Lophius Biosciences located in BioPark Regensburg has been able to successfully conclude a further round of financing for over 4.25 million €. With this fresh capital the focused development of a new diagnostic test to detect active tuberculosis will be financed.
(No. 168) With the support of REWAG an e-charging station has been set up at BioPark Regensburg. The "green" mayor Jürgen Huber took the opportunity to put the charging station into operation with his own i3 BMW company car to fill up with eco-electricity.
(No. 167) A delegation from Regensburg at the invitation of the partner city Tempe in the US Federal State of Arizona visited the biotechnology cluster there. At the moment the city is developing a similar BioPark project to Regensburg.
(No. 166) There is a newer, faster WLAN fiber optic hotspot from R-KOM operating at BioPark Regensburg. This makes it possible for all employees, visitors and participants at events in the lecture theater and conference area to use the internet at no cost for 2 hours per day.
(No. 166) The business field of sensor materials at the Fraunhofer EMFT in BioPark Regensburg is developing novel sensors for man and the environment. These have various areas of application in occupational safety, foodstuff safety and the early recognition of multiresistant pathogens.
(No. 165) The medical technology company located in the BioPark has developed a novel solution in the treatment of structural heart disease and valvular defects. The innovative technology portfolio has now been bought by the Chinese company Venus Medtech.
(No. 164) As part of its location analysis on the healthcare industry, BioPark Regensburg GmbH has supported a bachelor thesis at the Technical University of Deggendorf, which deals with the question regarding the establishment of a health tourism cluster.
(No. 163) The current development of the life science companies in the BioRegion Regensburg demonstrates a mild increase in the number of companies and rising numbers of employees. The new business figures presented by BioPark Regensburg GmbH for 2015 for the cluster in East Bavaria amount to 51 companies and 3,863 employees.